Sanofi India Ltd — Board/Management Information 2021

Feb 5, 2021

==> picture [89 x 71] intentionally omitted <==

5[th] February 2021

The Secretary The Secretary Bombay Stock Exchange Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5[th] Floor Dalal Street Plot No. C/1, G Block Mumbai 400 001 Bandra-Kurla Complex Bandra East, Mumbai 400 050

Proposed divestment of Soframycin® and Sofradex® businesses

Dear Sirs,

The Board of the Directors of Sanofi India Limited (the Company) at its meeting held today, reviewed the proposed plan of the Sanofi Group to globally sell some of its old brands along with their trademarks, which are owned by Sanofi Group. These include brands Soframycin® and Sofradex®, which are manufactured (through a third-party manufacturing arrangement) and distributed by the Company. The Board also noted that upon completion of such sale by Sanofi Group, the Company will not have the authority to distribute products under these brands.

The business of the Company under these brands was just 2.8% of the total sales of the Company for the nine months ended 30[th] September 2020.

The Board approved a review of options, and assessment of how best to monetise value for these businesses in India.

The Meeting of the Board of Directors commenced at 6.00 p.m. and concluded at 7.20 p.m.

Please take the above information on record.

Thanking you,

Yours sincerely, SANOFI INDIA LIMITED

==> picture [64 x 58] intentionally omitted <==

GIRISH TEKCHANDANI COMPANY SECRETARY

==> picture [468 x 13] intentionally omitted <==